Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 5:9:19.
doi: 10.1186/s40164-020-00175-1. eCollection 2020.

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study

Il Seok Daniel Jeong  1 , Huan Mo  2 , Anthony Nguyen  3 , Esther G Chong  4 , Hsin Hsiang Clarence Tsai  1 , Justin Moyers  3 , Matthew Kim  4 , Curtis Lacy  3 , Vivek Shah  4 , Eric Lau  3 , Yi Xu  5 , Huynh Cao  3
Affiliations

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study

Il Seok Daniel Jeong et al. Exp Hematol Oncol. .

Abstract

Objective: To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses.

Methods: We retrospectively reviewed patients from our center with locally advanced non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) who received primary chemoradiation with cisplatin or cetuximab between 2006 and 2018.

Results: The median OS for cisplatin (n = 66) was not reached versus 132 months when treated with cetuximab (n = 55) (p = 0.03). For HPV/p16-positive patients, we found the median OS for cisplatin (n = 34) was not reached versus 60 months with cetuximab (n = 21) (p = 0.036). In the smoking group, the median OS was not reached in the cisplatin group (n = 44) versus 60 months when treated with cetuximab (n = 32) (p = 0.03).

Conclusion: HPV/p16-positive and smoking cohorts treated with cisplatin-based chemoradiotherapy had a significantly better OS versus cetuximab.

Keywords: Cetuximab; Chemoradiation therapy; Cisplatin; HPV/p16; Head and neck squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient screening flowchart
Fig. 2
Fig. 2
Overall survival of (a) the overall study population, (b) the HPV/p16-positive population, (c) the smoking population, and (d) the advanced age population that received primary chemoradiation with cisplatin versus cetuximab
Fig. 2
Fig. 2
Overall survival of (a) the overall study population, (b) the HPV/p16-positive population, (c) the smoking population, and (d) the advanced age population that received primary chemoradiation with cisplatin versus cetuximab
Fig. 3
Fig. 3
Comparisons of EGFR expression levels of HNSCC cases in TCGA HNSC cohort based on HPV status and amplification (Amp) status of the EGFR gene region (x-axis). The EGFR expression level (y-axis) by RNA-sequencing is presented in RSEM scores [13] on a log2 scale
See this image and copyright information in PMC

References

    1. Falk RT, et al. Effect of smoking and alcohol consumption on laryngeal cancer risk in coastal Texas. Cancer Res. 1989;49(14):4024–4029. - PubMed
    1. Vokes EE, et al. Head and neck cancer. N Engl J Med. 1993;328(3):184–194. - PubMed
    1. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofacial Surg Clinics North Am. 2014;26(2):123–141. - PMC - PubMed
    1. Marur S, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–789. - PMC - PubMed
    1. Bachaud JM, et al. Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiation Oncol Biol Phy. 1996;36(5):999–1004. - PubMed

LinkOut - more resources